Evidence map›Paper›PMID 42218686›Full record

ReviewAnalytical chemistry2026

Trends in Computational Metabolomics: A Perspective on Five Years of Software Development, Challenges, and Opportunities (2021-2025).

Daniel Domingo-Fernández, David Healey, Tobias Kind, August Allen, Viswa Colluru, Biswapriya Biswavas Misra

Abstract readReview
In one paragraph

Review in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel Domingo-FernándezEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.ORCID 0000-0002-2046-6145
David HealeyEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.
Tobias KindEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.ORCID 0000-0002-1908-4916
August AllenEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.
Viswa ColluruEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.
Biswapriya Biswavas MisraEnveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301, United States.ORCID 0000-0003-2589-6539

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolomics software development has accelerated rapidly, yet no recent systematic analysis has quantified how the landscape is evolving across computational methods, geographies, and the research community's technology adoption. There is a strong need within the metabolomics research community to keep pace with the rapid expansion of accessible and free computational tools and resources. Given the absence of such a treatise since 2021 and the surge in advances in ion mobility mass spectrometry (IM-MS), single-cell and spatial metabolomics, and multimodal omics-based discovery, we offer a curated database that aggregates 746 mass spectrometry- and spectroscopy-based tools across 37 categories from data preprocessing to metabolite annotation. We report four structural shifts that redefine the field's trajectory. First, machine learning (ML) adoption in tools increased by 2.4-fold from 10.9% (2021) to 26.6% (2025). Second, annotation as a category commands the most tools (16.8%) and the highest ML investment among any of the proposed tool categories. The dominant strategy has shifted from library matching (2021) to spectrum prediction (2024) and, more recently, to de novo structure generation (2025), thereby progressively reducing the reliance on accessible experimental spectral reference databases. Third, Python has displaced R as the dominant programming language, with a sharp inflection in 2023 coinciding with the ML surge, while web server-only tools have sharply declined. Fourth, transformer architectures grew significantly, and in 2025, the first few large language model (LLM)-based and other multimodal metabolomics tools emerged, signaling a transition from task-specific classifiers toward pretrained, transferable representations. Concurrently, adoption of preprints as a publishing venue also rose by 2.5-fold, and, notably, mentions of benchmarking and explainability each increased by 8-18-fold, indicating a growing community-wide need and maturation. This computational metabolomics database is now made available here: https://github.com/enveda/computational-metabolomics-review.

Indexed as

MetabolomicsSoftwareDatabases, FactualMachine LearningMass Spectrometry

Identifiers

PMID42218686
PMCPMC13373924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.